Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus

Affiliations

• ¹ Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.
• ² Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
• ³ HIV-NAT, Thai Red Cross AIDS Research Centre and CE in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
• ⁴ Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
• ⁵ Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
• ⁶ Division of Infectious Diseases, McGovern Medical School, University of Texas, Houston, Texas, USA.
• ⁷ Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
• ⁸ Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
• ⁹ Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
• ¹⁰ DLH Corporation, Silver Spring, Maryland, USA.
• ¹¹ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
• ¹² Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.